Cargando…

CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients

Lung cancer is the common fatal illness with the highest incidence and mortality globally. Epidermal growth factor receptor overexpression by tumor cells is associated with uncontrolled proliferation, angiogenesis, anti-apoptotic signals, metastization, and invasiveness. CIMAvax-EGF vaccine consists...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saavedra, Danay, Crombet, Tania
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346887/ https://www.ncbi.nlm.nih.gov/pubmed/28348561 http://dx.doi.org/10.3389/fimmu.2017.00269

Ejemplares similares

Identifying predictive biomarkers of CIMAvaxEGF success in non–small cell lung cancer patients
por: Lorenzo-Luaces, Patricia, et al.
Publicado: (2020)

Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule
por: Popa, Xitlally, et al.
Publicado: (2020)

Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario
por: Flores Vega, Yoanna I., et al.
Publicado: (2023)

Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC
por: Evans, Rachel, et al.
Publicado: (2022)

Effect of blockade of the EGF system on wound healing in patients vaccinated with CIMAvax® EGF
por: Fernández Lorente, Aymara, et al.
Publicado: (2013)

The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer
por: Crombet Ramos, Tania, et al.
Publicado: (2021)

Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients
por: Rodriguez, Pedro C, et al.
Publicado: (2011)

T Cell Subpopulations in Healthy Elderly and Lung Cancer Patients: Insights from Cuban Studies
por: Saavedra, Danay, et al.
Publicado: (2017)

Characteristics of clinical trials for non-small cell lung cancer therapeutic vaccines registered on ClinicalTrials.gov
por: Gu, Wenyue, et al.
Publicado: (2022)

Control of Advanced Cancer: The Road to Chronicity
por: Lage, Agustin, et al.
Publicado: (2011)

Epigenetic Alterations and Inflammation as Emerging Use for the Advancement of Treatment in Non-Small Cell Lung Cancer
por: Yang, Shuo, et al.
Publicado: (2022)

Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer
por: Xing, Puyuan, et al.
Publicado: (2018)

The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
por: Ren, Sijia, et al.
Publicado: (2021)

Cryoablation and immunity in non-small cell lung cancer: a new era of cryo-immunotherapy
por: Velez, Antonio, et al.
Publicado: (2023)

Editorial: Advances in T Cell Therapeutic Vaccines for HIV
por: Macatangay, Bernard J. C., et al.
Publicado: (2022)

Therapeutic vaccines in non-small cell lung cancer
por: Socola, Francisco, et al.
Publicado: (2013)

Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer
por: Brunsvig, Paal F., et al.
Publicado: (2020)

Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer
por: Rao, Ding-Yu, et al.
Publicado: (2023)

Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors
por: Chen, Qian, et al.
Publicado: (2022)

Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis
por: Liu, Wenjie, et al.
Publicado: (2022)

Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects
por: Shi, Chunyan, et al.
Publicado: (2022)

Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors
por: Hu, Xiangxiao, et al.
Publicado: (2023)

Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer
por: He, Danming, et al.
Publicado: (2023)

Systemic Immune Activation and Responses of Irradiation to Different Metastatic Sites Combined With Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Wu, Min, et al.
Publicado: (2021)

Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-PD-1 inhibitors
por: Zhao, Xinmin, et al.
Publicado: (2022)

Case report: Brain metastasis necrosis with immune checkpoint inhibitors plus chemotherapy for advanced non-small cell lung cancer
por: Niu, Lishui, et al.
Publicado: (2022)

Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China
por: Zhang, Mengdie, et al.
Publicado: (2023)

Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer
por: Jacot, W, et al.
Publicado: (2004)

Targeting the EGF receptor family in non-small cell lung cancer—increased complexity and future perspectives
por: Boch, Tobias, et al.
Publicado: (2022)

Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy
por: Suárez, Gisela María, et al.
Publicado: (2022)

Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis
por: Li, Dan-Ni, et al.
Publicado: (2021)

Immune Cell Composition in Human Non-small Cell Lung Cancer
por: Stankovic, Branislava, et al.
Publicado: (2019)

Self-assembled nanoparticles: A new platform for revolutionizing therapeutic cancer vaccines
por: Shi, Tianyu, et al.
Publicado: (2023)

PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer
por: Memon, A A, et al.
Publicado: (2011)

Structure and Dynamics of the EGF Receptor as Revealed by Experiments and Simulations and Its Relevance to Non-Small Cell Lung Cancer
por: Martin-Fernandez, Marisa L., et al.
Publicado: (2019)

Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients
por: Yang, Qiao, et al.
Publicado: (2021)

Unique profile on the progress free survival and overall survival in patients with advanced non-small cell lung cancer in the Qujing area, Southwest China
por: Ma, Yuhui, et al.
Publicado: (2023)

Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer
por: Liang, Hongge, et al.
Publicado: (2022)

Sex difference in the expression of PD-1 of non-small cell lung cancer
por: Gu, Yong, et al.
Publicado: (2022)

Review: Mechanisms and perspective treatment of radioresistance in non-small cell lung cancer
por: Zhou, Ting, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e4j51omuglk833hp7kg9207u2s